Cook Medical Announces the Launch and First Patient Enrollment of the REFORM Clinical Trial

BLOOMINGTON, Ind.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved initiation of the REFORM clinical trial, officials of Cook Medical announced today. The REFORM trial is designed to evaluate the Formula™ Balloon Expandable Stent for the treatment of renal artery stenosis, a narrowing of the renal artery that can result in hypertension, renal atrophy, and kidney failure if left untreated.

MORE ON THIS TOPIC